A double-blind, randomised, dose ranging, multi-centre, phase IIIb study to evaluate the efficacy and safety of high doses of candesartan cilexetil (Atacand) on the reduction of proteinuria in the treatment of subjects with hypertension and moderate to severe proteinuria
Phase of Trial: Phase III
Latest Information Update: 17 Dec 2007
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- 17 Dec 2007 Status changed from in progress to completed.
- 10 Jan 2007 Status change
- 14 Nov 2005 New trial record.